The Pharmacogenomics of Clozapine-Induced Myocarditis (PROCLAIM)

Status: Ongoing
Project Lead: Chad Bousman (Principal Investigator) and Jess G. Fiedorowicz (Site Investigator)
Main Research Contact: Joe Burns

For some patients with schizophrenia for whom other treatments are ineffective, physicians use clozapine. Clozapine can induce myocarditis in a small percentage of patients. In this study, the research team is collecting blood samples from patients with clozapine-induced myocarditis in order to analyze these patient’s genomes and to generate induced pluripotent stem cells (iPSCs). The study team will use these iPSCs to create patient-specific cardiomyocytes and examine the effect of clozapine on these cardiomyocytes. The control group in this study consists of patients who received clozapine for treatment-resistant schizophrenia and did not develop myocarditis.